|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||296.64 - 302.21|
|52-week range||296.64 - 302.21|
|Beta (5Y monthly)||0.45|
|PE ratio (TTM)||0.31|
|Earnings date||31 Oct 2022 - 04 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Regeneron Pharmaceuticals (NASDAQ: REGN), Vertex Pharmaceuticals (NASDAQ: VRTX), and Biogen (NASDAQ: BIIB) are developing remarkable therapies that, instead of merely treating disorders, have the potential to cure them or at least make an impact that no other drug has to date. The reason that's not a big cause for alarm is that the company's second-quarter revenue of $2.86 billion would be up 20% over the same period in 2021 if its COVID-19 therapy, REGEN-COV, was excluded from total revenue. The company's sales of the treatment ended late last year when government contracts for the therapy ended.
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The two companies are collaborators, but they aren't equally likely to be a better purchase than Amazon.